Multiple lots of rejected Dexcom G7 sensors were stolen during the manufacturing disposal process, according to a new FDA safety alert. These devices represent a critical breach in quality assurance protocols, as they failed quality control standards and were designated as scrap material. The unauthorized removal of manufacturing rejects poses significant safety risks when such compromised devices enter clinical circulation outside approved channels.
Dexcom, which maintains approximately 70 percent market share in the global continuous glucose monitoring sector with 4.2 million active users worldwide, has prioritized notification of potentially affected patients. The FDA emphasizes that these particular sensor lots never received regulatory approval for patient use. The breach underscores vulnerabilities in medical device supply chain security and the importance of rigorous inventory control protocols. Healthcare providers are advised to implement verification procedures for device authenticity and patient safety.
Read the full article on GMJ Newsroom.
Was this article helpful?
